Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression
Overview
Affiliations
Since its original identification as a leukocyte gelatinase/type V collagenase and tumour type IV collagenase, gelatinase B/matrix metalloproteinase (MMP)-9 is now recognised as playing a central role in many aspects of tumour progression. In this review, we relate current concepts concerning the many ways in which gelatinase B/MMP-9 influences tumour biology. Following a brief outline of the gelatinase B/MMP-9 gene and protein, we analyse the role(s) of gelatinase B/MMP-9 in different phases of the tumorigenic process, and compare the importance of gelatinase B/MMP-9 source in the carcinogenic process. What becomes apparent is the importance of inflammatory cell-derived gelatinase B/MMP-9 in tumour promotion, early progression and triggering of the "angiogenic switch", the integral relationship between inflammatory, stromal and tumour components with respect to gelatinase B/MMP-9 production and activation, and the fundamental role for gelatinase B/MMP-9 in the formation and maintenance of tumour stem cell and metastatic niches. It is also apparent that gelatinase B/MMP-9 plays important tumour suppressing functions, producing endogenous angiogenesis inhibitors, promoting inflammatory anti-tumour activity, and inducing apoptosis. The fundamental roles of gelatinase B/MMP-9 in cancer biology underpins the need for specific therapeutic inhibitors of gelatinase B/MMP-9 function, the use of which must take into account and substitute for tumour-suppressing gelatinase B/MMP-9 activity and also limit inhibition of physiological gelatinase B/MMP-9 function.
Deciphering the oncogenic influence of : Implications of matrix metalloproteinase activation.
Nambiar J, Venugopal M, Shaji S, Bose C, Rajeev A, Kalliadan S Heliyon. 2025; 11(4):e42538.
PMID: 40028520 PMC: 11870157. DOI: 10.1016/j.heliyon.2025.e42538.
Hung C, Wang Y, Shih H, Liu C, He J, Chen J Cancer Genomics Proteomics. 2025; 22(2):258-270.
PMID: 39993804 PMC: 11880922. DOI: 10.21873/cgp.20500.
Zhang X, Ren X, Zhang S, Wang Y Exp Ther Med. 2024; 28(6):441.
PMID: 39583246 PMC: 11582528. DOI: 10.3892/etm.2024.12730.
Sivaganesh V, Ta T, Peethambaran B Int J Mol Sci. 2024; 25(13).
PMID: 39000112 PMC: 11241829. DOI: 10.3390/ijms25137003.
Association of Genotypes With Nasopharyngeal Carcinoma Risk.
Chen C, Shih L, Hsu S, Tien H, Liu Y, Wang Y In Vivo. 2024; 38(4):1731-1739.
PMID: 38936920 PMC: 11215630. DOI: 10.21873/invivo.13623.